Dr. Yaffe was interviewed by The Washington Post for an article, published this week, on breakthroughs in dementia diagnoses and treatment.
The Post delves into advances in dementia research from the past year. Included among the studies listed is the Yaffe Group's SMARRT trial, a personalized risk reduction trial investigating the use of a multidomain intervention targeting to reduce risk for dementia. The article also highlights other research focuses including the study of blood biomarkers, inflammation, risk reduction through vaccinations, and the use of lithium as a potentially neuroprotective therapy.
Read the article and Dr. Yaffe's comments here.